Company intelligence / Profile preview

Sciensus

Ownership: Private
Employees: ~700
Development stage: Commercial

Overview

Sciensus provides integrated patient access, engagement, logistics, real-world evidence generation, early access programs, decentralized trial support and homecare services to accelerate the development journey and maximize product value for biopharma clients in Europe. They do not conduct their own clinical trials or report clinical results as a sponsor.

Therapeutic areas: OncologyRare DiseasesOther
Modalities: Small moleculeBiologicOncology drugsRare disease therapies
Industry: Contract Research Organization

Partnerships

Works with over “50 pharma companies globally,” including partnerships with biopharma firms launching new medicines in Europe.Collaborates with CROs/CCOs on decentralized trials and early access programs.

Beyond the preview

Go deeper on Sciensus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sciensus.

Explore the full profile